Roche Holding, CH0012032048

Roche schedules third-quarter sales for Roche Holding stock

Published on 10/01/2026 at 12:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche posted CHF 30.4 billion sales in the first half of 2026, up 6.00 percent. Roche Holding stock has its next sales date on October 22, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH0012032048) has scheduled its third-quarter 2026 sales presentation for October 22, 2026, according to Roche. The date gives Roche Holding stock a defined operating checkpoint after first-half sales reached CHF 30.4 billion, up 6.00 percent at constant exchange rates.

Sales growth sets the baseline

Roche reported the first-half 2026 sales figure on its investor page and described the increase as constant-exchange-rate growth. The same update showed the Swiss franc effect separately, making the 6.00 percent operational comparison more informative than a currency-only reading.

The company also states that 39 million patients received Roche medicines in 2025, while customers received 31 billion diagnostic tests. Those figures underline the two-division structure behind the sales base, with pharmaceuticals and diagnostics contributing to the group’s global healthcare business.

Analysts disagree on valuation

Deutsche Bank maintained a Hold rating and a CHF 340.00 price target for Roche on September 30, 2026, according to finanzen.ch. Jefferies kept an Underperform rating with a CHF 230.00 target on September 29, 2026, according to finanzen.ch.

The spread between CHF 230.00 and CHF 340.00 shows how differently analysts weigh Roche’s pipeline, currency exposure and near-term execution. For investors, the October sales release will provide the next quantified test of whether the 6.00 percent first-half growth rate is carrying into the second half.

October sales provide the next test

Roche’s investor page lists the third-quarter sales presentation for October 22, 2026, at 2:00 p.m. CEST in Basel. The company’s investor overview also reports 11.00 percent core earnings per share growth at constant exchange rates in 2025, with diluted core earnings per share of CHF 19.46.